Dennis Kim
Geen lopende functies
Profiel
Dennis Kim served as Vice President-Clinical Development at Spectrum Pharmaceuticals, Inc. from 2013 to 2014.
He then worked as Chief Medical Officer at Talon Therapeutics, Inc. and Sesen Bio, Inc. He served as Chief Medical Officer at Panthera Corp.
from 2015 to 2018.
In 2014, he was Senior Vice President of North America Medical & Regulatory Affairs at Ipsen Biopharmaceuticals, Inc. Dr. Kim received his undergraduate degree from Harvard University, his doctorate from Stanford University, and his graduate degree from the University of California, Los Angeles.
Eerdere bekende functies van Dennis Kim
| Bedrijven | Functie | Einde |
|---|---|---|
Panthera Corp.
 Panthera Corp. Miscellaneous Commercial ServicesCommercial Services Panthera Corp. is a non-profit company that focuses on protecting wild cats by providing them with safe space, plentiful prey, and connection to other cats. Panthera is based in New York, NY and was founded by Thomas Scott Kaplan. The company values the Alliance for Wild Cats and encourages people to help protect wild cats for generations to come. | Hoofd Techniek/Wetenschap/O&O | 01-12-2018 |
| Ipsen Biopharmaceuticals, Inc. | Algemeen Adviseur | 01-12-2014 |
| SPECTRUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-07-2014 |
Talon Therapeutics, Inc.
 Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Hoofd Techniek/Wetenschap/O&O | - |
| CARISMA THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Dennis Kim
| Harvard University | Undergraduate Degree |
| Stanford University | Doctorate Degree |
| University of California, Los Angeles | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Panthera Corp.
Panthera Corp. Miscellaneous Commercial ServicesCommercial Services Panthera Corp. is a non-profit company that focuses on protecting wild cats by providing them with safe space, plentiful prey, and connection to other cats. Panthera is based in New York, NY and was founded by Thomas Scott Kaplan. The company values the Alliance for Wild Cats and encourages people to help protect wild cats for generations to come. | Commercial Services |
| Ipsen Biopharmaceuticals, Inc. | |
Talon Therapeutics, Inc.
Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Health Technology |
